A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic.
Identifieur interne : 001697 ( PubMed/Checkpoint ); précédent : 001696; suivant : 001698A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic.
Auteurs : Yuk-Fai Lau [Singapour] ; Lay-Hoon Tang ; Eng-Eong OoiSource :
- Vaccine [ 0264-410X ] ; 2009.
Descripteurs français
- KwdFr :
- ARN double brin (génétique), ARN viral (génétique), Administration par voie nasale, Animaux, Anticorps antiviraux (génétique), Anticorps antiviraux (immunologie), Flambées de maladies, Grippe chez les oiseaux (génétique), Grippe chez les oiseaux (immunologie), Grippe chez les oiseaux (virologie), Grippe humaine (immunologie), Grippe humaine (épidémiologie), Humains, Mâle, Oiseaux, Récepteur de type Toll-3 (génétique), Réplication virale, Souris, Souris de lignée BALB C, Sous-type H5N1 du virus de la grippe A (génétique), Sous-type H5N1 du virus de la grippe A (immunologie), Sous-type H5N1 du virus de la grippe A (pathogénicité), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (génétique), Vaccins antigrippaux (immunologie), Vaccins antigrippaux (usage thérapeutique), Vaccins inactivés (génétique), Vaccins inactivés (immunologie).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- génétique : ARN double brin, ARN viral, Anticorps antiviraux, Grippe chez les oiseaux, Récepteur de type Toll-3, Sous-type H5N1 du virus de la grippe A, Vaccins antigrippaux, Vaccins inactivés.
- immunologie : Anticorps antiviraux, Grippe chez les oiseaux, Grippe humaine, Sous-type H5N1 du virus de la grippe A, Vaccins antigrippaux, Vaccins inactivés.
- pathogénicité : Sous-type H5N1 du virus de la grippe A.
- usage thérapeutique : Vaccins antigrippaux.
- virologie : Grippe chez les oiseaux.
- épidémiologie : Grippe humaine.
- Administration par voie nasale, Animaux, Flambées de maladies, Humains, Mâle, Oiseaux, Réplication virale, Souris, Souris de lignée BALB C.
English descriptors
- KwdEn :
- Administration, Intranasal, Animals, Antibodies, Viral (genetics), Antibodies, Viral (immunology), Birds, Disease Outbreaks, Humans, Influenza A Virus, H5N1 Subtype (genetics), Influenza A Virus, H5N1 Subtype (immunology), Influenza A Virus, H5N1 Subtype (pathogenicity), Influenza Vaccines (administration & dosage), Influenza Vaccines (genetics), Influenza Vaccines (immunology), Influenza Vaccines (therapeutic use), Influenza in Birds (genetics), Influenza in Birds (immunology), Influenza in Birds (virology), Influenza, Human (epidemiology), Influenza, Human (immunology), Male, Mice, Mice, Inbred BALB C, RNA, Double-Stranded (genetics), RNA, Viral (genetics), Toll-Like Receptor 3 (genetics), Vaccines, Inactivated (genetics), Vaccines, Inactivated (immunology), Virus Replication.
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , genetics : Antibodies, Viral, Influenza Vaccines, RNA, Double-Stranded, RNA, Viral, Toll-Like Receptor 3, Vaccines, Inactivated.
- chemical , immunology : Antibodies, Viral, Influenza Vaccines, Vaccines, Inactivated.
- epidemiology : Influenza, Human.
- genetics : Influenza A Virus, H5N1 Subtype, Influenza in Birds.
- immunology : Influenza A Virus, H5N1 Subtype, Influenza in Birds, Influenza, Human.
- pathogenicity : Influenza A Virus, H5N1 Subtype.
- chemical , therapeutic use : Influenza Vaccines.
- virology : Influenza in Birds.
- Administration, Intranasal, Animals, Birds, Disease Outbreaks, Humans, Male, Mice, Mice, Inbred BALB C, Virus Replication.
Abstract
The appearance and spread of the H5N1 highly pathogenic avian influenza (HPAI) raise concern of a possible pandemic. Current preventive measures include the development of a pre-pandemic influenza vaccine and stockpiling of neuraminidase inhibitors. However, their benefits can be significantly reduced by mutations in the hemagglutinin or neuraminidase resulting in antigenic changes and the appearance of drug-resistance, respectively. Drugs that target the innate immune system to achieve a 'heightened antiviral' state represent another class of antiviral agents that could contribute to the control and treatment of influenza infection. In this study, PIKA (a stabilized dsRNA) provides broad-spectrum prophylaxis against a number of influenza A viruses. In addition, when PIKA was admixed with influenza vaccine preparations, including a formalin-inactivated whole-virion H5 vaccine, significant adjuvanting effect leading to accelerated viral clearance was observed in a murine model. These biological effects appear to be mediated by the ability of PIKA to promote the maturation of dendritic cells, including up-regulation of co-stimulatory molecules, such as CD80 and CD86, and the induction of various cytokines and chemokines. Toll-like receptor 3 (TLR3) was shown to recognize PIKA in a concentration-dependent manner. The potency and versatility in its activities make PIKA an attractive candidate for use in an influenza pandemic.
DOI: 10.1016/j.vaccine.2008.12.048
PubMed: 19150474
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:19150474Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic.</title>
<author><name sortKey="Lau, Yuk Fai" sort="Lau, Yuk Fai" uniqKey="Lau Y" first="Yuk-Fai" last="Lau">Yuk-Fai Lau</name>
<affiliation wicri:level="1"><nlm:affiliation>Medical Countermeasures (Biological) Laboratory, Defense Medical and Environmental Research Institute, DSO National Laboratories, 27 Medical Drive #13-00, The Republic of Singapore, 117510, Singapore. lyukfai@dso.org.sg</nlm:affiliation>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea>Medical Countermeasures (Biological) Laboratory, Defense Medical and Environmental Research Institute, DSO National Laboratories, 27 Medical Drive #13-00, The Republic of Singapore, 117510</wicri:regionArea>
<wicri:noRegion>117510</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tang, Lay Hoon" sort="Tang, Lay Hoon" uniqKey="Tang L" first="Lay-Hoon" last="Tang">Lay-Hoon Tang</name>
</author>
<author><name sortKey="Ooi, Eng Eong" sort="Ooi, Eng Eong" uniqKey="Ooi E" first="Eng-Eong" last="Ooi">Eng-Eong Ooi</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="RBID">pubmed:19150474</idno>
<idno type="pmid">19150474</idno>
<idno type="doi">10.1016/j.vaccine.2008.12.048</idno>
<idno type="wicri:Area/PubMed/Corpus">001827</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001827</idno>
<idno type="wicri:Area/PubMed/Curation">001827</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001827</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001697</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001697</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic.</title>
<author><name sortKey="Lau, Yuk Fai" sort="Lau, Yuk Fai" uniqKey="Lau Y" first="Yuk-Fai" last="Lau">Yuk-Fai Lau</name>
<affiliation wicri:level="1"><nlm:affiliation>Medical Countermeasures (Biological) Laboratory, Defense Medical and Environmental Research Institute, DSO National Laboratories, 27 Medical Drive #13-00, The Republic of Singapore, 117510, Singapore. lyukfai@dso.org.sg</nlm:affiliation>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea>Medical Countermeasures (Biological) Laboratory, Defense Medical and Environmental Research Institute, DSO National Laboratories, 27 Medical Drive #13-00, The Republic of Singapore, 117510</wicri:regionArea>
<wicri:noRegion>117510</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tang, Lay Hoon" sort="Tang, Lay Hoon" uniqKey="Tang L" first="Lay-Hoon" last="Tang">Lay-Hoon Tang</name>
</author>
<author><name sortKey="Ooi, Eng Eong" sort="Ooi, Eng Eong" uniqKey="Ooi E" first="Eng-Eong" last="Ooi">Eng-Eong Ooi</name>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal</term>
<term>Animals</term>
<term>Antibodies, Viral (genetics)</term>
<term>Antibodies, Viral (immunology)</term>
<term>Birds</term>
<term>Disease Outbreaks</term>
<term>Humans</term>
<term>Influenza A Virus, H5N1 Subtype (genetics)</term>
<term>Influenza A Virus, H5N1 Subtype (immunology)</term>
<term>Influenza A Virus, H5N1 Subtype (pathogenicity)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (genetics)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza Vaccines (therapeutic use)</term>
<term>Influenza in Birds (genetics)</term>
<term>Influenza in Birds (immunology)</term>
<term>Influenza in Birds (virology)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (immunology)</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>RNA, Double-Stranded (genetics)</term>
<term>RNA, Viral (genetics)</term>
<term>Toll-Like Receptor 3 (genetics)</term>
<term>Vaccines, Inactivated (genetics)</term>
<term>Vaccines, Inactivated (immunology)</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>ARN double brin (génétique)</term>
<term>ARN viral (génétique)</term>
<term>Administration par voie nasale</term>
<term>Animaux</term>
<term>Anticorps antiviraux (génétique)</term>
<term>Anticorps antiviraux (immunologie)</term>
<term>Flambées de maladies</term>
<term>Grippe chez les oiseaux (génétique)</term>
<term>Grippe chez les oiseaux (immunologie)</term>
<term>Grippe chez les oiseaux (virologie)</term>
<term>Grippe humaine (immunologie)</term>
<term>Grippe humaine (épidémiologie)</term>
<term>Humains</term>
<term>Mâle</term>
<term>Oiseaux</term>
<term>Récepteur de type Toll-3 (génétique)</term>
<term>Réplication virale</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Sous-type H5N1 du virus de la grippe A (génétique)</term>
<term>Sous-type H5N1 du virus de la grippe A (immunologie)</term>
<term>Sous-type H5N1 du virus de la grippe A (pathogénicité)</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins antigrippaux (génétique)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins antigrippaux (usage thérapeutique)</term>
<term>Vaccins inactivés (génétique)</term>
<term>Vaccins inactivés (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Antibodies, Viral</term>
<term>Influenza Vaccines</term>
<term>RNA, Double-Stranded</term>
<term>RNA, Viral</term>
<term>Toll-Like Receptor 3</term>
<term>Vaccines, Inactivated</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term>
<term>Influenza Vaccines</term>
<term>Vaccines, Inactivated</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H5N1 Subtype</term>
<term>Influenza in Birds</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>ARN double brin</term>
<term>ARN viral</term>
<term>Anticorps antiviraux</term>
<term>Grippe chez les oiseaux</term>
<term>Récepteur de type Toll-3</term>
<term>Sous-type H5N1 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins inactivés</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Grippe chez les oiseaux</term>
<term>Grippe humaine</term>
<term>Sous-type H5N1 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins inactivés</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H5N1 Subtype</term>
<term>Influenza in Birds</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Influenza A Virus, H5N1 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Sous-type H5N1 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe chez les oiseaux</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza in Birds</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term>
<term>Animals</term>
<term>Birds</term>
<term>Disease Outbreaks</term>
<term>Humans</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Administration par voie nasale</term>
<term>Animaux</term>
<term>Flambées de maladies</term>
<term>Humains</term>
<term>Mâle</term>
<term>Oiseaux</term>
<term>Réplication virale</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The appearance and spread of the H5N1 highly pathogenic avian influenza (HPAI) raise concern of a possible pandemic. Current preventive measures include the development of a pre-pandemic influenza vaccine and stockpiling of neuraminidase inhibitors. However, their benefits can be significantly reduced by mutations in the hemagglutinin or neuraminidase resulting in antigenic changes and the appearance of drug-resistance, respectively. Drugs that target the innate immune system to achieve a 'heightened antiviral' state represent another class of antiviral agents that could contribute to the control and treatment of influenza infection. In this study, PIKA (a stabilized dsRNA) provides broad-spectrum prophylaxis against a number of influenza A viruses. In addition, when PIKA was admixed with influenza vaccine preparations, including a formalin-inactivated whole-virion H5 vaccine, significant adjuvanting effect leading to accelerated viral clearance was observed in a murine model. These biological effects appear to be mediated by the ability of PIKA to promote the maturation of dendritic cells, including up-regulation of co-stimulatory molecules, such as CD80 and CD86, and the induction of various cytokines and chemokines. Toll-like receptor 3 (TLR3) was shown to recognize PIKA in a concentration-dependent manner. The potency and versatility in its activities make PIKA an attractive candidate for use in an influenza pandemic.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19150474</PMID>
<DateCompleted><Year>2009</Year>
<Month>04</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0264-410X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>27</Volume>
<Issue>9</Issue>
<PubDate><Year>2009</Year>
<Month>Feb</Month>
<Day>25</Day>
</PubDate>
</JournalIssue>
<Title>Vaccine</Title>
<ISOAbbreviation>Vaccine</ISOAbbreviation>
</Journal>
<ArticleTitle>A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic.</ArticleTitle>
<Pagination><MedlinePgn>1354-64</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2008.12.048</ELocationID>
<Abstract><AbstractText>The appearance and spread of the H5N1 highly pathogenic avian influenza (HPAI) raise concern of a possible pandemic. Current preventive measures include the development of a pre-pandemic influenza vaccine and stockpiling of neuraminidase inhibitors. However, their benefits can be significantly reduced by mutations in the hemagglutinin or neuraminidase resulting in antigenic changes and the appearance of drug-resistance, respectively. Drugs that target the innate immune system to achieve a 'heightened antiviral' state represent another class of antiviral agents that could contribute to the control and treatment of influenza infection. In this study, PIKA (a stabilized dsRNA) provides broad-spectrum prophylaxis against a number of influenza A viruses. In addition, when PIKA was admixed with influenza vaccine preparations, including a formalin-inactivated whole-virion H5 vaccine, significant adjuvanting effect leading to accelerated viral clearance was observed in a murine model. These biological effects appear to be mediated by the ability of PIKA to promote the maturation of dendritic cells, including up-regulation of co-stimulatory molecules, such as CD80 and CD86, and the induction of various cytokines and chemokines. Toll-like receptor 3 (TLR3) was shown to recognize PIKA in a concentration-dependent manner. The potency and versatility in its activities make PIKA an attractive candidate for use in an influenza pandemic.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lau</LastName>
<ForeName>Yuk-Fai</ForeName>
<Initials>YF</Initials>
<AffiliationInfo><Affiliation>Medical Countermeasures (Biological) Laboratory, Defense Medical and Environmental Research Institute, DSO National Laboratories, 27 Medical Drive #13-00, The Republic of Singapore, 117510, Singapore. lyukfai@dso.org.sg</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tang</LastName>
<ForeName>Lay-Hoon</ForeName>
<Initials>LH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ooi</LastName>
<ForeName>Eng-Eong</ForeName>
<Initials>EE</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2009</Year>
<Month>01</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Vaccine</MedlineTA>
<NlmUniqueID>8406899</NlmUniqueID>
<ISSNLinking>0264-410X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012330">RNA, Double-Stranded</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C519703">TLR3 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051196">Toll-Like Receptor 3</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001717" MajorTopicYN="N">Birds</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053124" MajorTopicYN="N">Influenza A Virus, H5N1 Subtype</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005585" MajorTopicYN="N">Influenza in Birds</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012330" MajorTopicYN="N">RNA, Double-Stranded</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051196" MajorTopicYN="N">Toll-Like Receptor 3</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year>
<Month>08</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2008</Year>
<Month>12</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2008</Year>
<Month>12</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>1</Month>
<Day>20</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>1</Month>
<Day>20</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2009</Year>
<Month>4</Month>
<Day>25</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">19150474</ArticleId>
<ArticleId IdType="pii">S0264-410X(08)01775-1</ArticleId>
<ArticleId IdType="doi">10.1016/j.vaccine.2008.12.048</ArticleId>
<ArticleId IdType="pmc">PMC7115584</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2000 May 23;97(11):6108-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10801978</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2001 Oct 18;413(6857):732-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11607032</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2007 Sep;13(9):1354-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18252107</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Allergy Clin Immunol. 2006 Sep;118(3):641-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16950283</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Cell Mol Biol. 2004 Sep;31(3):358-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15191912</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2006 May 20;367(9523):1657-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16714186</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2006 Jun 15;193(12):1626-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16703504</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1992 Apr;66(4):2564-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1548781</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antivir Chem Chemother. 2004 Mar;15(2):101-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15185728</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Respir J. 1998 Feb;11(2):324-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9551732</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vet Rec. 2006 Mar 4;158(9):309-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16517825</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 1998 Feb 14;351(9101):472-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9482438</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 1989 Apr;27(4):293-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2656909</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antivir Chem Chemother. 2006;17(5):275-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17176632</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2003 Apr 2;21(15):1687-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12639491</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2006 Jun;2(6):e53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16789835</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1986 Dec;155(2):625-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2431541</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Immun. 1984 Feb;43(2):457-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6693167</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Rev. 2004 Dec;202:8-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15546383</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2005 Dec 22;353(25):2667-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16371632</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2001 Jul 16;19(28-29):4072-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11427284</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2006 Jun;80(12):5976-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16731936</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2007 Aug 18;370(9587):580-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17707753</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2005 Mar 18;23(17-18):2266-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15755608</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2006 Apr;6(4):186-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16554238</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Mol Immunol. 2007 Apr;4(2):113-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17484805</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2007 Nov 1;196(9):1313-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17922395</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2007 Nov;81(22):12418-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17855542</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Natl Cancer Inst. 1976 Sep;57(3):599-602</Citation>
<ArticleIdList><ArticleId IdType="pubmed">978771</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2001 Jun 16;357(9272):1937-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11425416</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Otolaryngol. 2007 Apr;127(4):395-402</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17453460</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2001 Sep 6;413(6851):78-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11544529</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Rev. 2000 Feb;173:89-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10719670</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2006 Jul;12(7):1167-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16845780</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1980 Feb 14;283(5748):660-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7354853</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2006 Sep;25(3):349-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16979567</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2004 Dec 16;23(5):615-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15542181</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2004 Jul;5(7):730-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15208624</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2007 Aug;81(16):8774-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17553867</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2006 Nov 1;194 Suppl 2:S111-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17163383</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 Apr 20;25(16):3175-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17280757</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Top Microbiol Immunol. 2006;311:1-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17048703</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Leukoc Biol. 1997 Apr;61(4):415-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9103227</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microbiol Immunol. 2007;51(11):1099-107</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18037787</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Virus Res. 1993;42:57-102</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7679242</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int Immunol. 2007 Mar;19(3):311-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17289654</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2002 Feb;3(2):196-200</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11812998</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2003 Feb;77(3):2046-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12525639</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Immun. 2005 May;73(5):3044-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15845512</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 1994 Sep;38(9):2059-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7811019</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2005 Sep 29;353(13):1374-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16192482</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2005 Oct 20;437(7062):1108</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16228009</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2007 Oct 15;179(8):5220-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17911607</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Methods. 2001 Dec;25(4):386-401</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11846608</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 1988 May;32(5):678-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2840014</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2006 Mar 30;354(13):1343-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16571878</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 1997 Jan 20;185(2):317-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9016880</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Singapour</li>
</country>
</list>
<tree><noCountry><name sortKey="Ooi, Eng Eong" sort="Ooi, Eng Eong" uniqKey="Ooi E" first="Eng-Eong" last="Ooi">Eng-Eong Ooi</name>
<name sortKey="Tang, Lay Hoon" sort="Tang, Lay Hoon" uniqKey="Tang L" first="Lay-Hoon" last="Tang">Lay-Hoon Tang</name>
</noCountry>
<country name="Singapour"><noRegion><name sortKey="Lau, Yuk Fai" sort="Lau, Yuk Fai" uniqKey="Lau Y" first="Yuk-Fai" last="Lau">Yuk-Fai Lau</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001697 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001697 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= PandemieGrippaleV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:19150474 |texte= A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:19150474" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a PandemieGrippaleV1
![]() | This area was generated with Dilib version V0.6.34. | ![]() |